↓ Skip to main content

Dove Medical Press

Article Metrics

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology

Overview of attention for article published in Therapeutics and Clinical Risk Management, July 2021
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
42 Mendeley
Title
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
Published in
Therapeutics and Clinical Risk Management, July 2021
DOI 10.2147/tcrm.s282390
Pubmed ID
Authors

Chiara Rosa Mancinelli, Nicola De Rossi, Ruggero Capra

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 14%
Student > Ph. D. Student 4 10%
Student > Master 4 10%
Other 2 5%
Professor 2 5%
Other 9 21%
Unknown 15 36%
Readers by discipline Count As %
Medicine and Dentistry 9 21%
Neuroscience 5 12%
Biochemistry, Genetics and Molecular Biology 3 7%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Unspecified 2 5%
Other 6 14%
Unknown 15 36%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2022.
All research outputs
#17,415,169
of 22,330,240 outputs
Outputs from Therapeutics and Clinical Risk Management
#952
of 1,251 outputs
Outputs of similar age
#237,820
of 343,288 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#3
of 3 outputs
Altmetric has tracked 22,330,240 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,251 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,288 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.